e-Therapeutics Plc, is a drug discovery and development company, which engages in the provision of evaluation services to investors and pharmaceutical companies. The company focuses on the therapeutic immune-oncology, addressing drug resistance in targeted cancer therapies and antivirals. It offers the following variety of preclinical stage assets: ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule anti-TNFa; ETS2400, Hedgehog pathway inhibition; and ETS5200, broad spectrum antivirals together with two immuno-oncology checkpoint projects. The company was founded by Malcolm Philip Young on October 15, 2001 and is headquartered in London, the United Kingdom.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company